H
Heikki Ristolainen
Researcher at University of Helsinki
Publications - 12
Citations - 959
Heikki Ristolainen is an academic researcher from University of Helsinki. The author has contributed to research in topics: Microsatellite instability & Mutation frequency. The author has an hindex of 9, co-authored 12 publications receiving 810 citations.
Papers
More filters
Journal ArticleDOI
CTCF/cohesin-binding sites are frequently mutated in cancer
Riku Katainen,Kashyap Dave,Esa Pitkänen,Kimmo Palin,Teemu Kivioja,Niko Välimäki,Alexandra E. Gylfe,Heikki Ristolainen,Ulrika A. Hänninen,Tatiana Cajuso,Johanna Kondelin,Tomas Tanskanen,Jukka-Pekka Mecklin,Heikki Järvinen,Laura Renkonen-Sinisalo,Laura Renkonen-Sinisalo,Anna Lepistö,Eevi Kaasinen,Outi Kilpivaara,Sari Tuupanen,Martin Enge,Jussi Taipale,Jussi Taipale,Lauri A. Aaltonen +23 more
TL;DR: Analysis of public data showed that multiple cancer types accumulate CBS mutations, and integration of whole-genome sequencing data from 213 colorectal cancer samples and chromatin immunoprecipitation sequencing data identified frequent point mutations at CBSs.
Journal ArticleDOI
Characterization of uterine leiomyomas by whole-genome sequencing.
Miika Mehine,Eevi Kaasinen,Netta Mäkinen,Riku Katainen,Kati Kämpjärvi,Esa Pitkänen,Hanna-Riikka Heinonen,Ralf Bützow,Outi Kilpivaara,Anna Kuosmanen,Heikki Ristolainen,Massimiliano Gentile,Jari Sjöberg,Pia Vahteristo,Lauri A. Aaltonen +14 more
TL;DR: Chromosome shattering and reassembly resembling chromothripsis is a major cause of chromosomal abnormalities in uterine leiomyomas and it is proposed that tumorigenesis occurs when tissue-specific tumor-promoting changes are formed through these events.
Journal ArticleDOI
Exome sequencing reveals frequent inactivating mutations in ARID1A, ARID1B, ARID2 and ARID4A in microsatellite unstable colorectal cancer.
Tatiana Cajuso,Ulrika A. Hänninen,Johanna Kondelin,Alexandra E. Gylfe,Tomas Tanskanen,Riku Katainen,Esa Pitkänen,Heikki Ristolainen,Eevi Kaasinen,Minna Taipale,Minna Taipale,Jussi Taipale,Jussi Taipale,Jan Böhm,Laura Renkonen-Sinisalo,Jukka-Pekka Mecklin,Heikki Järvinen,Sari Tuupanen,Outi Kilpivaara,Pia Vahteristo +19 more
TL;DR: The results indicate that in addition to ARID1A, other members of the ARID gene family may play a role in MSI CRC, and the mutations were distributed along the entire length of the gene, thus distinguishing them from typical MSI target genes previously described.
Journal ArticleDOI
Impact of constitutional TET2 haploinsufficiency on molecular and clinical phenotype in humans.
Eevi Kaasinen,Outi Kuismin,Outi Kuismin,Kristiina Rajamäki,Heikki Ristolainen,Mervi Aavikko,Johanna Kondelin,Silva Saarinen,Davide G. Berta,Riku Katainen,Elina A. M. Hirvonen,Auli Karhu,Aurora Taira,Tomas Tanskanen,Amjad Alkodsi,Minna Taipale,Ekaterina Morgunova,Kaarle Franssila,Rainer Lehtonen,Markus J. Mäkinen,Kristiina Aittomäki,Aarno Palotie,Aarno Palotie,Aarno Palotie,Mitja I. Kurki,Olli Pietilainen,Morgane Hilpert,Elmo Saarentaus,Jaakko Niinimäki,Jaakko Niinimäki,Juhani Junttila,Kari Kaikkonen,Pia Vahteristo,Radek C. Skoda,Mikko Seppänen,Kari K. Eklund,Jussi Taipale,Jussi Taipale,Outi Kilpivaara,Lauri A. Aaltonen,Lauri A. Aaltonen +40 more
TL;DR: Findings provide insight into the interplay between epigenetic modulators and transcription factor activity in hematological neoplasia, but do not confirm the putative role of TET2 in atherosclerosis.
Journal ArticleDOI
Identification of Candidate Oncogenes in Human Colorectal Cancers With Microsatellite Instability
Alexandra E. Gylfe,Johanna Kondelin,Mikko P. Turunen,Heikki Ristolainen,Riku Katainen,Esa Pitkänen,Eevi Kaasinen,Ville Rantanen,Tomas Tanskanen,Markku Varjosalo,Heli J. Lehtonen,Kimmo Palin,Minna Taipale,Jussi Taipale,Laura Renkonen–Sinisalo,Heikki Järvinen,Jan Böhm,Jukka-Pekka Mecklin,Ari Ristimäki,Outi Kilpivaara,Sari Tuupanen,Auli Karhu,Pia Vahteristo,Lauri A. Aaltonen +23 more
TL;DR: The exomes of 25 colorectal tumors and respective healthy colon tissue were sequenced to detect new oncogenes and ZBTB2, RANBP2, and PSRC1 found to contain hot spot mutations in the validation set, which might be used to develop personalized tumor profiling and therapy.